You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Patent: 11,491,223


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,491,223
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Understanding the Claims and Patent Landscape of United States Patent 11,491,223

Introduction

When analyzing a patent, particularly one like United States Patent 11,491,223, it is crucial to delve into the claims, the patent landscape, and the legal framework that governs patent law in the United States. This analysis will help in understanding the patent's validity, its position within the broader patent landscape, and potential challenges it might face.

The Patent Claims

To begin with, it is essential to examine the claims of the patent in question. Patent claims define the scope of the invention and are critical in determining what is protected by the patent. Here are some key points to consider:

Novelty Requirement

The claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[4].

Nonobviousness Requirement

Even if the invention is novel, it must also be nonobvious. This means that the invention must be significantly different from existing technology and not obvious to a person of ordinary skill in the relevant field[4].

Subject Matter Eligibility

The patent claims must also be directed to eligible subject matter. This involves ensuring that the claims are not directed to laws of nature, natural phenomena, or abstract ideas unless they contain an "inventive concept" that transforms the nature of the claim[1].

Patent Landscape and Prior Art

Understanding the patent landscape involves identifying prior art that could potentially anticipate or render the claimed invention obvious.

Prior Art Analysis

Prior art includes all publicly available information that existed before the effective filing date of the patent application. If every element of the claimed invention is already disclosed in the prior art, the claim may be rejected as anticipated[4].

Inter Partes Review (IPR) and Post-Grant Review (PGR)

The Leahy-Smith America Invents Act (AIA) introduced IPR and PGR, which allow for administrative challenges to the validity of patents. These processes are often faster and less expensive than judicial proceedings and require a lower burden of proof to invalidate patents[1].

Legal Framework and Challenges

The legal framework governing patents in the United States is complex and includes various avenues for challenging patent validity.

Patent Trial and Appeal Board (PTAB)

The PTAB, established by the AIA, is a tribunal within the USPTO that hears administrative challenges to patent validity, including IPR and PGR. These challenges can be initiated by anyone, providing a more efficient and cost-effective alternative to federal court litigation[1].

Federal Court Litigation

In federal court, patents carry a presumption of validity, and invalidity must be proven by clear and convincing evidence. This process is typically more time-consuming and expensive compared to PTAB proceedings[1].

Role of Inventorship

Inventorship is a critical aspect of patent law, and any issues related to it can significantly impact the patent's validity.

Correct Inventorship

Ensuring that all inventors are correctly named is essential. Failure to do so can lead to patent invalidity. For example, in the case of Blue Gentian, LLC v. Tristar Products, Inc., the district court determined that a nonparty should have been named as a co-inventor, leading to the correction of the patents[2].

AI and Inventorship

With the increasing use of AI tools in patent drafting, there is a need to ensure that AI contributions do not undermine the inventorship requirements. The USPTO has issued guidance emphasizing the need to disclose any material use of AI tools and to verify the accuracy of all statements and evidence submitted[3].

Practical Implications and Strategies

For businesses and inventors, understanding the claims and the patent landscape is crucial for strategic decision-making.

Defending Against Infringement Claims

If a company is accused of patent infringement, it may choose to challenge the patent's validity through IPR or PGR before the PTAB, which can be more advantageous than litigating in federal court[1].

Ensuring Compliance with USPTO Guidelines

Practitioners must ensure that all documents submitted to the USPTO, including those assisted by AI tools, are carefully reviewed to avoid inaccuracies and omissions that could affect patentability[3].

Key Takeaways

  • Patent Claims: The claims define the scope of the invention and must meet novelty, nonobviousness, and subject matter eligibility requirements.
  • Patent Landscape: Understanding prior art and the broader patent landscape is crucial for assessing the validity of the patent.
  • Legal Framework: The AIA introduced IPR and PGR, providing alternative avenues for challenging patent validity.
  • Inventorship: Correct inventorship is essential, and the use of AI tools must be disclosed and verified to ensure compliance with USPTO guidelines.
  • Strategic Decision-Making: Businesses must consider the practical implications of patent challenges and ensure compliance with all relevant regulations.

FAQs

  1. What is the significance of the Leahy-Smith America Invents Act (AIA) in patent law? The AIA is widely viewed as the most significant patent statute enacted by Congress in over 50 years, introducing administrative challenges like IPR and PGR to improve patent quality and efficiency[1].

  2. How does the Patent Trial and Appeal Board (PTAB) differ from federal court litigation? PTAB processes are typically faster and less expensive, requiring a lower burden of proof to invalidate patents compared to federal court litigation[1].

  3. What are the implications of using AI tools in patent drafting? The use of AI tools must be disclosed, and all statements and evidence must be verified to ensure accuracy and compliance with USPTO guidelines[3].

  4. Why is correct inventorship important in patent law? Correct inventorship is essential to avoid patent invalidity. Failure to name all inventors correctly can lead to legal challenges and corrections[2].

  5. How does the novelty requirement impact patent claims? The novelty requirement ensures that the claimed invention must not have been patented, described in a printed publication, or in public use before the effective filing date of the claimed invention[4].

Sources

  1. Congressional Research Service. The Patent Trial and Appeal Board and Inter Partes Review. Updated May 28, 2024.
  2. United States Court of Appeals for the Federal Circuit. BLUE GENTIAN, LLC v. TRISTAR PRODUCTS, INC. June 9, 2023.
  3. Buchanan Ingersoll & Rooney PC. U.S. Patent Office Issues Additional Guidance on Use of AI Tools. April 15, 2024.
  4. United States Patent and Trademark Office. MPEP § 2131 - Anticipation — Application of 35 U.S.C. 102. R-08.2017.

More… ↓

⤷  Subscribe

Details for Patent 11,491,223

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 ⤷  Subscribe
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 ⤷  Subscribe
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 ⤷  Subscribe
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 ⤷  Subscribe
Immunex Corporation ENBREL MINI etanercept Injection 103795 September 14, 2017 ⤷  Subscribe
Immunex Corporation ENBREL etanercept Injection 103795 ⤷  Subscribe
Immunex Corporation ENBREL etanercept Injection 103795 March 05, 2020 ⤷  Subscribe
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.